Drug Approval | March 01, 2024
Biocon Biologics secures US market entry date for Bmab 1200
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The plant will drive pharmaceutical innovation in the Northeastern India
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
‘Unmask Anemia’ aims to simplify assessment of iron deficiency anemia risk with an easy online self-test based on common signs and symptoms
Varenicline is indicated for smoking cessation in adults
The said Unit complies with the prescribed Good Manufacturing practices as per relevant WHO technical Report Series
Leishmaniasis is caused by protozoan parasites which are transmitted by the bite of infected female phlebotomine sandflies
VeerHealth Care will be raising Rs. 8 crores through bank borrowings
Subscribe To Our Newsletter & Stay Updated
